BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26675717)

  • 21. ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer.
    Mendaza S; Ulazia-Garmendia A; Monreal-Santesteban I; Córdoba A; Azúa YR; Aguiar B; Beloqui R; Armendáriz P; Arriola M; Martín-Sánchez E; Guerrero-Setas D
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wnt signaling in triple negative breast cancer is associated with metastasis.
    Dey N; Barwick BG; Moreno CS; Ordanic-Kodani M; Chen Z; Oprea-Ilies G; Tang W; Catzavelos C; Kerstann KF; Sledge GW; Abramovitz M; Bouzyk M; De P; Leyland-Jones BR
    BMC Cancer; 2013 Nov; 13():537. PubMed ID: 24209998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Jepperson T; Willis S; Leyland-Jones B; Dey N
    Oncotarget; 2017 Jan; 8(2):3072-3103. PubMed ID: 27902969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. β1 Integrin is essential for fascin-mediated breast cancer stem cell function and disease progression.
    Barnawi R; Al-Khaldi S; Colak D; Tulbah A; Al-Tweigeri T; Fallatah M; Monies D; Ghebeh H; Al-Alwan M
    Int J Cancer; 2019 Aug; 145(3):830-841. PubMed ID: 30719702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological Characteristics and Clinical Significance of ITGB1 and RHOC in Patients With Recurrent Colorectal Cancer.
    Ha YJ; Tak KH; Kim SK; Kim CW; Lee JL; Roh SA; Cho DH; Kim SY; Kim YS; Kim JC
    Anticancer Res; 2019 Sep; 39(9):4853-4864. PubMed ID: 31519588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.
    Kannan A; Philley JV; Hertweck KL; Ndetan H; Singh KP; Sivakumar S; Wells RB; Vadlamudi RK; Dasgupta S
    Sci Rep; 2019 Aug; 9(1):11632. PubMed ID: 31406142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.
    Gao C; Li H; Liu C; Xu X; Zhuang J; Zhou C; Liu L; Feng F; Sun C
    Front Immunol; 2021; 12():650491. PubMed ID: 33968045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Expression of
    Deng H; Huang Y; Wang L; Chen M
    Biomed Res Int; 2020; 2020():2071593. PubMed ID: 33134373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.
    Al-Khadairi G; Naik A; Thomas R; Al-Sulaiti B; Rizly S; Decock J
    J Transl Med; 2019 Jan; 17(1):9. PubMed ID: 30602372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of tRNA-derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple-negative breast cancer.
    Feng W; Li Y; Chu J; Li J; Zhang Y; Ding X; Fu Z; Li W; Huang X; Yin Y
    Cancer Med; 2018 Oct; 7(10):5130-5144. PubMed ID: 30239174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
    Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
    Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of NuSAP1 is predictive of an unfavourable prognosis and promotes proliferation and invasion of triple-negative breast cancer cells via the Wnt/β-catenin/EMT signalling axis.
    Sun L; Shi C; Liu S; Zhang E; Yan L; Ji C; Zhao Y
    Gene; 2020 Jul; 747():144657. PubMed ID: 32298762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
    BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.
    Schüler-Toprak S; Häring J; Inwald EC; Moehle C; Ortmann O; Treeck O
    BMC Cancer; 2016 Dec; 16(1):951. PubMed ID: 28003019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FRZB is Regulated by the Transcription Factor EGR1 and Inhibits the Growth and Invasion of Triple-Negative Breast Cancer Cells by Regulating the JAK/STAT3 Pathway.
    Liu H; Mei Y; Ma X; Zhang X; Nie W
    Clin Breast Cancer; 2022 Oct; 22(7):690-698. PubMed ID: 35787980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. siRNA-mediated suppression of collagen type iv alpha 2 (COL4A2) mRNA inhibits triple-negative breast cancer cell proliferation and migration.
    JingSong H; Hong G; Yang J; Duo Z; Li F; WeiCai C; XueYing L; YouSheng M; YiWen O; Yue P; Zou C
    Oncotarget; 2017 Jan; 8(2):2585-2593. PubMed ID: 27906681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.